Advertisement

Topics

Overall survival analysis of carfilzomib in ENDEAVOR trial published

07:20 EDT 24 Aug 2017 | ecancermedicalscience

Results from an overall survival (OS) analysis of the Phase 3 head-to-head ENDEAVOR trial were published online first in The Lancet Oncology. Data showed that carfilzomib administered at 56 mg/m2 twice weekly and dexamethasone reduced the risk of death...

Original Article: Overall survival analysis of carfilzomib in ENDEAVOR trial published

NEXT ARTICLE

More From BioPortfolio on "Overall survival analysis of carfilzomib in ENDEAVOR trial published"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...